SEARCH
Growth momentum to continue in Q2, H2 due to trastuzumab launch, says Biocon
CNBC-TV18
2019-07-26
Views
60
Description
Share / Embed
Download This Video
Report
Biocon reported a good quarter with the company's biologics business growing quarter on quarter (QoQ) and margins come in-line. Kiran Mazumdar Shaw, CMD of Biocon shared her views and outlook.
Show more
Share This Video
facebook
google
twitter
linkedin
email
Video Link
Embed Video
<iframe width="600" height="350" src="https://dailytv.net//embed/x7ec8l7" frameborder="0" allowfullscreen></iframe>
Preview Player
Download
Report form
Reason
Your Email address
Submit
RELATED VIDEOS
15:23
Q2 Review: Can JB Continue Growth Momentum In Q3? | BQPrime
36:23
Yes Bank’s Growth Momentum May Continue In Q2
15:02
Q2 Review| Can Persistent System Continue Strong Growth Momentum
01:21
Biocon Q4FY19 numbers: Expect strong earnings momentum to continue
15:03
Talking Point: Cipla's CFO On Q2 Report Card & H2 Growth Outlook
13:59
Tata Steel CFO On Q2 Report Card & H2 Growth Projections
14:41
Tata Power MD On Q2 Report Card & H2 Growth Projections
13:01
HDFC Life's MD On Q2 Report Card & H2 Growth Outlook: Talking Point
00:44
Adobe Q2 Earnings: Revenue Beat, EPS Beat, Strong Guidance, Momentum Due To 'Highly Differentiated Approach To AI' And More
23:22
After A Stellar Q2, Can IDFC First Continue Momentum In Q3?
03:05
Disaster Stock Of The Day: Diageo hares are trading lower after the company said it expects slower growth in H1 FY24 than H2 FY23 due to weaker conditions in Latin America and Caribbean
36:25
Bhupinder Singh Hooda: Hope new government continue Haryana's growth momentum